Influence of body mass index on recurrence and quality of life in atrial fibrillation patients after catheter ablation: A meta-analysis and systematic review

Clinical Cardiology

Volumn 36, Issue 5, 2013, Pages 269-275

  Zhuang, Jianhui ^a   Lu, Yuyan ^a   Tang, Kai ^a   Peng, Wenhui ^a   Xu, Yawei ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BODY MASS; CATHETER ABLATION; CLINICAL TRIAL (TOPIC); COCHRANE LIBRARY; EMBASE; HEART ATRIUM FIBRILLATION; HUMAN; MEDLINE; META ANALYSIS; PAROXYSMAL HEART ATRIUM FIBRILLATION; PULMONARY VEIN ISOLATION; QUALITY OF LIFE; RECURRENCE RISK; RECURRENT DISEASE; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ADVERSE EFFECTS; ATRIAL FIBRILLATION; OBESITY; ODDS RATIO; PATHOPHYSIOLOGY; PSYCHOLOGY; RISK FACTOR; TIME FACTOR;

ATRIAL FIBRILLATION; BODY MASS INDEX; CATHETER ABLATION; HUMANS; OBESITY; ODDS RATIO; QUALITY OF LIFE; RECURRENCE; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84877741918     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22108     Document Type: Review

References (35)

1. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol. 2006; 26: 968-976.
2. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003; 289: 76-79.
3. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002; 347: 305-313.
4. Wang TJ, Parise H, Levy D, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA. 2004; 292: 2471-2477.
5. Wanahita N, Messerli FH, Bangalore S, et al. Atrial fibrillation and obesity-results of a meta-analysis. Am Heart J. 2008; 155: 310-315.
6. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994; 271: 840-844.
7. Noheria A, Kumar A, Wylie JV Jr, et al. Catheter ablation vs antiarrhythmic drug therapy for atrial fibrillation: a systematic review. Arch Intern Med. 2008; 168: 581-586.
8. Piccini JP, Lopes RD, Kong MH, et al. Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation: a meta-analysis of randomized, controlled trials. Circ Arrhythm Electrophysiol. 2009; 2: 626-633.
9. Calkins H, Reynolds MR, Spector P, et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol. 2009; 2: 349-361.
10. Jais P, Cauchemez B, Macle L, et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation. 2008; 118: 2498-2505.
11. Oral H, Pappone C, Chugh A, et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med. 2006; 354: 934-941.
12. Cai L, Yin Y, Ling Z, et al. Predictors of late recurrence of atrial fibrillation after catheter ablation [published online ahead of print July 6, 2011]. Int J Cardiol. doi: 10.1016/j.ijcard.2011.06.094. Available at: http://www.internationaljournalofcardiology.com.
13. Cha YM, Friedman PA, Asirvatham SJ, et al. Catheter ablation for atrial fibrillation in patients with obesity. Circulation. 2008; 117: 2583-2590.
14. Letsas KP, Weber R, Burkle G, et al. Pre-ablative predictors of atrial fibrillation recurrence following pulmonary vein isolation: the potential role of inflammation. Europace. 2009; 11: 158-163.
15. Letsas KP, Siklõdy CH, Korantzopoulos P, et al. The impact of body mass index on the efficacy and safety of catheter ablation of atrial fibrillation [published online ahead of print July 2, 2011]. Int J Cardiol. 2011. doi: 10.1016/j.ijcard.2011.06.092. Available at: http://www. internationaljournalofcardiology.com.
16. Tang RB, Dong JZ, Liu XP, et al. Metabolic syndrome and risk of recurrence of atrial fibrillation after catheter ablation. Circ J. 2009; 73: 438-443.
17. Tang RB, Dong JZ, Liu XP, et al. Obstructive sleep apnoea risk profile and the risk of recurrence of atrial fibrillation after catheter ablation. Europace. 2009; 11: 100-105.
18. Chilukuri K, Dalal D, Gadrey S, et al. A prospective study evaluating the role of obesity and obstructive sleep apnea for outcomes after catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2010; 21: 521-525.
19. Hoyer FF, Lickfett LM, Mittmann-Braun E, et al. High prevalence of obstructive sleep apnea in patients with resistant paroxysmal atrial fibrillation after pulmonary vein isolation. J Interv Card Electrophysiol. 2010; 29: 37-41.
20. Okumura Y, Watanabe I, Nakai T, et al. Impact of biomarkers of inflammation and extracellular matrix turnover on the outcome of atrial fibrillation ablation: importance of matrix metalloproteinase-2 as a predictor of atrial fibrillation recurrence. J Cardiovasc Electrophysiol. 2011; 22: 987-993.
21. Shin SY, Na JO, Lim HE, et al. Improved endothelial function in patients with atrial fibrillation through maintenance of sinus rhythm by successful catheter ablation. J Cardiovasc Electrophysiol. 2010; 22: 376-382.
22. Wokhlu A, Monahan KH, Hodge DO, et al. Long-term quality of life after ablation of atrial fibrillation the impact of recurrence, symptom relief, and placebo effect. J Am Coll Cardiol. 2010; 55: 2308-2316.
23. Mohanty S, Mohanty P, Di Biase L, et al. Influence of body mass index on quality of life in atrial fibrillation patients undergoing catheter ablation. Heart Rhythm. 2011; 8: 1847-1852.
24. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283: 2008-2012.
25. Wells GA, Shea B, O'Connell D, et al. Ottawa Hospital Research Institute. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. http://www.ohri.ca/programs/clinical-epidemiology/ oxford.htm. Accessed January 1, 2008.
26. Begg CB, Mazumdar M,. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50: 1088-1101.
27. Tedrow UB, Conen D, Ridker PM, et al. The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation: the WHS (Women's Health Study). J Am Coll Cardiol. 2010; 55: 2319-2327.
28. Wilber DJ, Pappone C, Neuzil P, et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA. 2010; 303: 333-340.
29. Ng CY, Liu T, Shehata M, et al. Meta-analysis of obstructive sleep apnea as predictor of atrial fibrillation recurrence after catheter ablation. Am J Cardiol. 2011; 108: 47-51.
30. Zhuang J, Wang Y, Tang K, et al. Association between left atrial size and atrial fibrillation recurrence after single circumferential pulmonary vein isolation: a systematic review and meta-analysis of observational studies. Europace. 2012; 14: 638-645.
31. Kurotobi T, Iwakura K, Inoue K, et al. A pre-existent elevated C-reactive protein is associated with the recurrence of atrial tachyarrhythmias after catheter ablation in patients with atrial fibrillation. Europace. 2010; 12: 1213-1218.
32. Groenveld HF, Crijns HJ, Van den Berg MP, et al. The effect of rate control on quality of life in patients with permanent atrial fibrillation: data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study. J Am Coll Cardiol. 2011; 58: 1795-1803.
33. Reynolds MR, Walczak J, White SA, et al. Improvements in symptoms and quality of life in patients with paroxysmal atrial fibrillation treated with radiofrequency catheter ablation versus antiarrhythmic drugs. Circ Cardiovasc Qual Outcomes. 2010; 3: 615-623.
34. Al Chekakie MO, Akar JG, Wang F, et al. The effects of statins and renin-angiotensin system blockers on atrial fibrillation recurrence following antral pulmonary vein isolation. J Cardiovasc Electrophysiol. 2007; 18: 942-946.
35. Savelieva I, Camm AJ,. Upstream therapies after pulmonary vein ablation: five negative studies-what's next? Europace. 2010; 12: 1509-1513.